X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Details:
ENV105 (carotuximab) is a novel ENG inhibitor monoclonal antibody. It is currently being evaluated in phase 1 clinical trials in combination with osimertinib for the treatment of non-small cell lung cancer.
Lead Product(s): Carotuximab,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: ENV105
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is being evaluated in combination with chemotherapy in phase 3 clinical trials for the treatment of EGFR-mutated advanced lung cancer and brain metastases.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Cisplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2023
Details:
Tagrisso (osimertinib) is kinase inhibitor of the epidermal growth factor receptor (EGFR), which is investigated in combination with chemotherapy for patients with EGFR-mutated advanced lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
BBP-398 is a potential best-in-class SHP2 inhibitor being developed in combination with AstraZeneca’s osimertinib, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with non-small cell lung cancer (NSCLC) with EGFR mutations.
Lead Product(s): BBP-398,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
Details:
The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor, in combination with AstraZeneca’s osimertinib, an EGFR inhibitor, in Phase 1 clinical study for the treatment of patients with non-small cell lung cancer with EGFR mutations.
Lead Product(s): BBP-398,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BBP-398
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 12, 2023
Details:
BL-B01D1 is a first-in-class bispecific antibody-drug conjugate developed by SystImmune, targeting both EGFR and HER3, proteins that are highly expressed in most epithelial tumors.
Lead Product(s): BL-B01D1,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BL-B01D1
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2023
Details:
Reqorsa Immunogene Therapy (quaratusugene ozeplasmid)uses Genprex’s unique, proprietary ONCOPREX® Nanoparticle Delivery System Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer
Lead Product(s): Quaratusugene Ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 30, 2023
Details:
Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases. It is being investigated in patient with Stage IIIB-IIIC or Stage IV epidermal growth factor receptor-mutated NSCLC.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
Tagrisso (osimertinib) is kinase inhibitor of the epidermal growth factor receptor (EGFR), it has exhibited anti-tumor activity against NSCLC lines harboring EGFR-mutations.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2023
Details:
REQORSA Immunogene Therapy (quaratusugene ozeplasmid) for non-small cell lung cancer (NSCLC) uses Genprex’s unique, proprietary ONCOPREX® Nanoparticle Delivery System, which is the first systemic gene therapy delivery platform used for cancer in human clinical trials.
Lead Product(s): Quaratusugene Ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
Exploratory results showed TAGRISSO (osimertinib) also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2022
Details:
Preliminary results from SAVANNAH Phase II trial showed that TAGRISSO® (osimertinib) plus savolitinib demonstrated an ORR of 49% in patients with epidermal growth factor receptor-mutated NSCLC with high levels of mesenchymal epithelial transition overexpression.
Lead Product(s): Osimertinib Mesylate,Savolitinib
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Analysis utilizing GuardantINFORM™ real-world evidence platform shows cumulative incidence of EGFR C797X mutation was 12.5 percent in NSCLC patients likely to progress after first-line Tagrisso (osimertinib) treatment.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Blueprint Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
The results from SAVANNAH suggest savolitinib added to Tagrisso (osimertinib) at the time of disease progression could possibly provide these biomarker-selected patients with a potentially less toxic, more effective treatment option.
Lead Product(s): Osimertinib Mesylate,Savolitinib
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hutchmed
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
Savolitinib (ORPATHYS), is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors, blocks atypical activation of MET receptor tyrosine kinase pathway.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
Under the terms of agreement, Biocartis and AstraZeneca will co-lead the development and applicable premarket notification or approval of the Idylla™ EGFR CDx Assay intended for patients with nonsmall cell lung cancer who may respond to treatment with Tagrisso (osimertinib).
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2022
Details:
EMB-01(FIT-013a) is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. EMB-01 has demonstrated efficacy in multiple preclinical models.
Lead Product(s): FIT-013a,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: EMB-01
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Collaboration with AstraZeneca to investigate the combination of SI-B001 and a leading third-generation EGFR TKI for patients with NSCLC. By combining SI-B001 with Osimertinib, we believe it has the potential to provide more effective treatment options for patients with NSCLC.
Lead Product(s): SI-B001,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: SI-B001
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 13, 2022
Details:
Preclinical data supporting the potential of its farnesyl transferase inhibitor (FTI) tipifarnib to prevent emergence of resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib in EGFR mutant non-small cell lung cancer (NSCLC).
Lead Product(s): Tipifarnib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Zarnesta
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2022
Details:
This milestone has been triggered by the initiation of SAFFRON, the first global Phase III study for ORPATHYS in combination with TAGRISSO in EGFR - mutated non-small cell lung cancer patients with mesenchymal epithelial transition receptor driven tumors.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: $140.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 06, 2022
Details:
Acclaim-1 clinical trial evaluating REQORSA, a pan-kinase inhibitor shown to inhibit both EGFR and AKT oncogenic kinase pathways in combination with Tagrisso in patients with late-stage NSCLC with activating epidermal growth factor receptor mutations.
Lead Product(s): Quaratusugene Ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
SACHI, a China Phase III study of ORPATHYS® (savolitinib), an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”), in combination with AstraZeneca’s third-generation, irreversible epidermal growth factor receptor (“EGFR”) TKI, TAGRISSO® (osimertinib).
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2021
Details:
The study will evaluate the efficacy and safety of TAGRISSO® in combination with ORPATHYS® comparing to TAGRISSO® alone, a standard-of-care treatment option for these patients.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Orpathys
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
The approval by European Commission was based on positive results from ADAURA Phase III trial in which Tagrisso demonstrated a clinically significant improvement in disease-free survival in primary analysis population of patients with Stage II and IIIA EGFRm NSCLC.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2021
Details:
UK medicines regulator issues its first authorisation for Osimertinib (Tagrisso), a medicine made by AstraZeneca, is a licensed treatment for patients with mid and later stage non-small cell lung cancer (NSCLC) who test positive for a specific gene mutation called EGFR.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2021
Details:
Newly licensed technologies include use of Genprex’s TUSC2 gene therapy combined with EGFR inhibitors or other anti-cancer therapies in patients predicted to be responsive to TUSC2 therapy. TUSC2 gene-expressing plasmid is the active agent in REQORSA immunogene therapy.
Lead Product(s): Quaratusugene ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 06, 2021
Details:
Tagrisso showed a statistically significant and clinically meaningful improvement in disease-free survival in the primary analysis population of patients with Stage II and IIIA EGFRm NSCLC, and in the overall trial population of patients with Stage IB-IIIA disease.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2021
Details:
Tagrisso is the only targeted medicine to show efficacy in the treatment of early-stage lung cancer in a global trial and the first such medicine approved in China.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2021
Details:
China MediTech Limited will sell its entire indirect interest in Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited (“HBYS”), a non-core and non-consolidated OTC drug joint venture business which includes Osimertinib.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: HMPL-504
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GL Mountrose Investment Two
Deal Size: $169.0 million Upfront Cash: Undisclosed
Deal Type: Divestment March 24, 2021
Details:
In this exploratory analysis of the overall trial population, adjuvant Tagrisso reduced the risk of disease recurrence or death by 84% in patients who had been treated with prior adjuvant chemotherapy and by 77% in patients who had not.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2021
Details:
Genprex has passed all of the final release tests for its first scaled-up clinical-grade manufacturing run of REQORSA™ immunogene therapy, in advance of its upcoming Acclaim-1 and Acclaim-2 clinical trials for the treatment of non-small cell lung cancer.
Lead Product(s): Quaratusugene ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
For the first time, REQORSA was manufactured in a scaled-up clinical production in accordance with the current Good Manufacturing Practices (cGMP) required by the U.S. Food and Drug Administration (FDA) in advance of commercial approval of a drug product.
Lead Product(s): Quaratusugene ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2020
Details:
The approval based on ADAURA Phase III trial where Tagrisso showed a statistically significant and clinically meaningful improvement in disease-free survival in patients with Stage II and IIIA EGFRm NSCLC, andoverall trial population of patients with Stage IB-IIIA disease.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
REQORSA is comprised of TUSC2 plasmid DNA (the active agent in REQORSA) encapsulated in non-viral nanoparticles that are administered intravenously and designed to target tumor cells.
Lead Product(s): Quaratusugene ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2020
Details:
Genprex’s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors.
Lead Product(s): Quaratusugene ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
New branding will support upcoming combination clinical trials, including the Company’s trial combining REQORSA™ immunogene therapy drug with AstraZeneca’s Tagrisso®, which received FDA Fast Track Designation earlier in 2020.
Lead Product(s): Quaratusugene ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: GPX-001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
Details:
REQORSA immunogene therapy uses the company’s unique, proprietary ONCOPREX® nanoparticle delivery system to deliver cancer-fighting genes.
Lead Product(s): Quaratusugene ozeplasmid,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Reqorsa
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Unprecedented results show treatment with Tagrisso reduced the risk of disease recurrence or death by 80% in ADAURA Phase III trial.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
Fewer patients treated with Tagrisso in the adjuvant setting had recurrence events or deaths compared to placebo (11% versus 46%). Among patients whose cancer recurred, 38% of those treated with Tagrisso had a metastatic recurrence compared to 61% of patients on placebo.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Tagrisso
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2020
Details:
The new preclinical data showed BLU-945 potently and selectively inhibited triple-mutant EGFR harboring the most common on-target resistance mutations to standard treatments for EGFRm NSCLC, resulting in robust anti-tumor activity in multiple lung cancer models.
Lead Product(s): BLU-945,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: BLU-945
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
Sequential Gilotrif® (afatinib) and osimertinib contributed to a median overall survival (OS) of nearly four years among U.S. patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer and the common resistance mutation, T790M.
Lead Product(s): Afatinib,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Gilotrif
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
The collaboration aims to evaluate the combination of patritumab deruxtecan (U3-1402) and TAGRISSO (osimertinib) in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC).
Lead Product(s): Patritumab Deruxtecan,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: U3-1402
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 06, 2020
Details:
Manufacturing program supports upcoming clinical trials, including Oncoprex in combination with Tagrisso®, which received FDA Fast Track Designation.
Lead Product(s): Oncoprex,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Oncoprex
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
Genprex will deliver an overview of the Company and provide updates on its product pipeline, including its lead drug candidate, Oncoprex™ immunogene therapy, which received Fast Track Designation from the FDA for its combination therapy with AstraZeneca’s Tagrisso®.
Lead Product(s): Oncoprex,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2020
Details:
The funding will be used for the planned clinical trial of Genprex's lead gene therapy drug candidate, Oncoprex™ immunogene therapy, combined with targeted therapy Tagrisso® in non-small cell lung cancer (NSCLC) patients whose tumors progressed on Tagrisso.
Lead Product(s): Oncoprex,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
